Flagship Pioneering And Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk To Develop Next-Generation Therapeutics for Obesity Management, Novo Nordisk May Pay Up To $600M In Upfront, Development, And Commercial Milestone Payments
旗舰先锋和隐喻生物技术公司宣布与诺和诺德合作开发下一代肥胖管理疗法,诺和诺德可能支付高达6亿美元的预付款、开发和商业里程碑款项